🎯 Median PFS of 38.2 vs 8.4 months: first-line pembrolizumab monotherapy beat carboplatin/paclitaxel in dMMR advanced or recurrent endometrial cancer in the phase 3 KEYNOTE-C93 tri

OncLive.com· @OncLive · X·2026-10-27 02:42· 4 小时前评分70

正文 · 原文

🎯 Median PFS of 38.2 vs 8.4 months: first-line pembrolizumab monotherapy beat carboplatin/paclitaxel in dMMR advanced or recurrent endometrial cancer in the phase 3 KEYNOTE-C93 trial (HR, 0.57). Full ESMO 2026 data 👇 #ESMO26 #gyncsm @myESMO @GynCancerMD @MountSinaiMiami https://hubs.li/Q04CmvxT0

64 浏览 · 0 赞 · 1 转发 · 0 回复

来源：OncLive.com · x.com